GSR Ventures
A GSR Ventures survey revealed 71% of investors believe the tech is changing their investment strategy "somewhat," and 17% say it changes their strategy "significantly."
During Venture Connect at HIMSS23, panelists discussed the future of digital therapeutics.
Though funding has fallen this year, Dr. Sunny Kumar, partner at GSR Ventures, said there are still opportunities for startups that can prove their value.
A GSR Ventures survey of 50 investors reveals return on investment and clinical validation would be vital to a company's success next year.
GSR Ventures led the round with participation from sequoia Capital, Storm Ventures, NextGen Venture Partners and BIXINK Therapeutics.
This new investment brings the company's total funding to $45 million.
GSR Venture US led the round with participation from Arsenal Growth and existing investors.